Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: A potential role for IGF-1R de-repression

Journal of Neuro-Oncology

Volumn 103, Issue 1, 2011, Pages 87-102

  Chen, Mike Y ^a,b   Clark, Aaron J ^a,b   Chan, Dana C ^a,b   Ware, Joy L ^b   Holt, Shawn E ^b   Chidambaram, Archana ^b   Fillmore, Helen L ^a,b   Broaddus, William C ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Chemosensitivity; Glioblastoma; IGF 1R; RNA interference; Wilms' tumor 1

Indexed keywords

CARMUSTINE; CISPLATIN; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC REGULATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; RECEPTOR UPREGULATION; SENESCENCE; TUMOR SUPPRESSOR GENE; WILMS TUMOR 1 GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CARMUSTINE; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; HUMANS; PROMOTER REGIONS, GENETIC; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; WT1 PROTEINS;

EID: 79960017227     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0374-7     Document Type: Article

References (80)

1. Surawicz TS, McCarthy BJ, Kupelian V et al (1999) Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1:14-25
2. Ballman KV, Buckner JC, Brown PD et al (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9(1):29-38 (Pubitemid 46543486)
3. Surawicz TS, Davis F, Freels S et al (1998) Brain tumor survival: results from the national cancer data base. J Neurooncol 40:151-160 (Pubitemid 29010168)
4. Loeb DM, Evron E, Patel CB et al (2001) Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 61:921-925 (Pubitemid 32174404)
5. Miwa H, Beran M, Saunders GF (1992) Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6(5):405-409 Abstract
6. Nakahara Y, Okamoto H, Mineta T et al (2004) Expression of the Wilms' tumor gene product WT1 in glioblastomas and medulloblastomas. Brain Tumor Pathol 21:113-116 (Pubitemid 40187985)
7. Oji Y, Suzuki T, Nakano Y et al (2004) Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Sci 95:822-827 (Pubitemid 39545589)
8. Zhang L, Lau YK, Xia W et al (1999) Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5:343-353 (Pubitemid 29085188)
9. Clark AJ, Dos Santos WG, McCready J et al (2007) Wilms tumor 1 expression in malignant gliomas and correlation of ?KTS isoforms with p53 status. J Neurosurg 107:586-592 (Pubitemid 47451043)
10. Armstrong JF, Pritchard-Jones K, Bickmore WA et al (1993) The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech Dev 40:85-97
11. Pritchard-Jones K, Fleming S, Davidson D et al (1990) The candidate Wilms' tumour gene is involved in genitourinary development. Nature 346:194-197
12. Haber DA, Sohn RL, Buckler AJ et al (1991) Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 88:9618-9622 (Pubitemid 21915682)
13. Scharnhorst V, Dekker P, van der Eb AJ et al (1999) Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties. J Biol Chem 274:23456-23462
14. Sharma PM, Bowman M, Madden SL et al (1994) RNA editing in the Wilms' tumor susceptibility gene, WT1. Genes Dev 8: 720-731 (Pubitemid 24116766)
15. Call KM, Glaser T, Ito CY et al (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520
16. Keilholz U, Menssen HD, Gaiger A et al (2005) Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 19(8):1318-1323 (Pubitemid 41136321)
17. Wagner KJ, Roberts SG (2004) Transcriptional regulation by the Wilms' tumour suppressor protein WT1. Biochem Soc Trans 32:932-935 (Pubitemid 39655508)
18. Davies RC, Calvio C, Bratt E et al (1998) WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 12:3217-3225 (Pubitemid 28496266)
19. Caricasole A, Duarte A, Larsson SH et al (1996) RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc Natl Acad Sci USA 93:7562-7566 (Pubitemid 26277075)
20. Spraggon L, Dudnakova T, Slight J et al (2007) hnRNP-U directly interacts with WT1 and modulates WT1 transcriptional activation. Oncogene 26(10):1484-1491 (Pubitemid 46340810)
21. Maheswaran S, Englert C, Bennett P et al (1995) The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 9:2143-2156
22. Johnstone RW, See RH, Sells SF et al (1996) A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 16: 6945-6956 (Pubitemid 26389754)
23. Scharnhorst V, Dekker P, van der Eb AJ et al (2000) Physical interaction between Wilms tumor 1 and p73 proteins modulates their functions. J Biol Chem 275:10202-10211 (Pubitemid 30202076)
24. Algar EM, Khromykh T, Smith SI et al (1996) A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 12:1005-1014 (Pubitemid 26104442)
25. Oji Y, Nakamori S, Fujikawa M et al (2004) Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci. 95:583-587 (Pubitemid 39089639)
26. Tuna M, Chavez-Reyes A, Tari AM (2005) HER2/neu increases the expression of Wilms' tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene 24:1648-1652 (Pubitemid 40396095)
27. Zapata-Benavides P, Tuna M, Lopez-Berestein G et al (2002) Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun 295:784-790
28. Oji Y, Ogawa H, Tamaki H et al (1999) Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 90:194-204 (Pubitemid 29112320)
29. Ware j, Roberts C, Richardson A, London C, Kroecher A, Amantana A, Devi G (2005) WT1: a novel target for antisense mediated prostate tumor therapy (Abstract #594). Poster presentation American Association of Cancer Research 2005, Anaheim CA, 16/04/2005
30. Mayo MW, Wang CY, Drouin SS et al (1999) WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 protooncogene. EMBO J 18:3990-4003 (Pubitemid 29335852)
31. Hewitt SM, Hamada S, McDonnell TJ et al (1995) Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 55:5386-5389
32. Heckman C, Mochon E, Arcinas M et al (1997) The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas. J Biol Chem 272:19609-19614 (Pubitemid 27337765)
33. Loeb DM (2006) WT1 influences apoptosis through transcriptional regulation of Bcl-2 family members. Cell Cycle 5: 1249-1253 (Pubitemid 43894273)
34. Damon SE, Plymate SR, Carroll JM et al (2001) Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 142:21-27 (Pubitemid 32183661)
35. Idelman G, Glaser T, Roberts CT Jr et al (2003) WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation. J Biol Chem 278:3474-3482 (Pubitemid 36801264)
36. Tajinda K, Carroll J, Roberts CT Jr (1999) Regulation of insulinlike growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor. Endocrinology 140:4713-4724 (Pubitemid 30666139)
37. Chen Y, Douglass T, Jeffes EW et al (2002) Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a ''paraptosis''-induced pathway that promotes systemic immunity against intracranial T9 gliomas. Blood 100:1373-1380 (Pubitemid 34864294)
38. Jadus MR, Chen Y, Boldaji MT et al (2003) Human U251MG glioma cells expressing the membrane form of macrophage colony- stimulating factor (mM-CSF) are killed by human monocytes in vitro and are rejected within immunodeficient mice via paraptosis that is associated with increased expression of three different heat shock proteins. Cancer Gene Ther 10:411-420 (Pubitemid 36528785)
39. Sperandio S, de BI, Bredesen DE (2000) An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 97:14376-14381 (Pubitemid 32016583)
40. Sperandio S, Poksay K, de BI et al (2004) Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ 11:1066-1075 (Pubitemid 39341632)
41. Liu Y, Lehar S, Corvi C et al (1998) Expression of the insulinlike growth factor I receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells. Cancer Res 58:570-576 (Pubitemid 28087424)
42. Hata Y, Sandler A, Loehrer PJ et al (1994) Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency. Oncol Res 6:19-24
43. Mochan TA, Venere M, DiTullio RA Jr et al (2003) 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res 63:8586-8591 (Pubitemid 38064030)
44. Morrison AJ, Highland J, Krogan NJ et al (2004) INO80 and gamma-H2AX interaction links ATP-dependent chromatin remodeling to DNA damage repair. Cell 119:767-775 (Pubitemid 40017684)
45. Ito H, Daido S, Kanzawa T et al (2005) Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int J Oncol 26:1401-1410
46. Kanzawa T, Kondo Y, Ito H et al (2003) Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63:2103-2108 (Pubitemid 36538613)
47. Chi S, Kitanaka C, Noguchi K et al (1999) Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene 18:2281-2290 (Pubitemid 29186929)
48. Kanzawa T, Germano IM, Komata T et al (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11:448-457 (Pubitemid 38489422)
49. Ito H, Aoki H, Kuhnel F et al (2006) Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 98:625-636 (Pubitemid 43904846)
50. Katayama M, Kawaguchi T, Berger MS et al (2007) DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14:548-558
51. Abedin MJ, Wang D, McDonnell MA et al (2007) Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 14:500-510
52. Kreidberg JA, Sariola H, Loring JM et al (1993) WT-1 is required for early kidney development. Cell 74:679-691 (Pubitemid 23259748)
53. Izumoto S, Tsuboi A, Oka Y et al (2008) Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963-971 (Pubitemid 351656845)
54. Englert C, Hou X, Maheswaran S et al (1995) WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 14:4662-4675
55. Han Y, San Marina S, Liu J et al (2004) Transcriptional activation of c-myc proto-oncogene byWT1 protein. Oncogene 23:6933-6941 (Pubitemid 39279994)
56. Liu XW, Gong LJ, Guo LY et al (2001) The Wilms' tumor gene product WT1 mediates the down-regulation of the rat epidermal growth factor receptor by nerve growth factor in PC12 cells. J Biol Chem 276:5068-5073
57. Drummond IA, Madden SL, Rohwer-Nutter P et al (1992) Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257:674-678
58. Gashler AL, Bonthron DT, Madden SL et al (1992) Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci USA 89:10984-10988
59. Nichols KE, Re GG, Yan YX et al (1995) WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res 55:4540-4543
60. Broaddus WC, Liu Y, Steele LL et al (1999) Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction. J Neurosurg 91:997-1004
61. Ishii N, Maier D, Merlo A et al (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469-479 (Pubitemid 29316287)
62. Shahrabani-Gargir L, Pandita TK, Werner H (2004) Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology 145:5679-5687 (Pubitemid 39564610)
63. Morrison DJ, English MA, Licht JD (2005) WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak. Cancer Res 65:8174-8182 (Pubitemid 41330581)
64. Rodeck U, Bossler A, Kari C et al (1994) Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes. Int J Cancer 59:78-82
65. Wang W, Lee SB, Palmer R et al (2001) A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1. J Biol Chem 276:16810-16816
66. Simpson LA, Burwell EA, Thompson KA et al (2006) The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood 107:4695-4702 (Pubitemid 43882617)
67. Ito K, Oji Y, Tatsumi N et al (2006) Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 25:4217-4229 (Pubitemid 44079455)
68. Daido S, Kanzawa T, Yamamoto A et al (2004) Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. Cancer Res 64:4286-4293 (Pubitemid 38802435)
69. Takeuchi H, Kondo Y, Fujiwara K et al (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65:3336-3346 (Pubitemid 40524618)
70. Loeb DM, Korz D, Katsnelson M et al (2002) Cyclin E is a target of WT1 transcriptional repression. J Biol Chem 277:19627-19632 (Pubitemid 34967476)
71. Englert C, Maheswaran S, Garvin AJ et al (1997) Induction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res 57:1429-1434 (Pubitemid 27175555)
72. Werner H, Roberts CT Jr, Rauscher FJ III et al (1996) Regulation of insulin-like growth factor I receptor gene expression by the Wilms' tumor suppressor WT1. J Mol Neurosci 7:111-123 (Pubitemid 126718441)
73. Hongo A, Yumet G, Resnicoff M et al (1998) Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by the stable expression of a myristylated COOH terminus of the insulin-like growth factor I receptor. Cancer Res 58:2477-2484 (Pubitemid 28252712)
74. Plymate SR, Bae VL, Maddison L et al (1997) Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 138:1728-1735 (Pubitemid 27137128)
75. Plymate SS, Bae VL, Maddison L et al (1997) Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis. Endocrine. 7:119-124 (Pubitemid 127483101)
76. Van Meter et al (2004) AKT inhibition enhances BCNU-mediated death in astrocytoma cells independent of PTEN functional status. Poster presentation. Congress of neurological surgeons, Annual meeting and 6th biennial AANS/CNS joint tumor satellite symposium, San Francisco CA, 21/10/2004
77. Simpson JR, Horton J, Scott C et al (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26:239-244 (Pubitemid 23156970)
78. Walker MD, Alexander E Jr, Hunt WE et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333-343 (Pubitemid 9013313)
79. Mains RE, May V (1988) The role of a low pH intracellular compartment in the processing, storage, and secretion of ACTH and endorphin. J Biol Chem 263:7887-7894
80. Paglin S, Hollister T, Delohery T et al (2001) A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61:439-444 (Pubitemid 32128593)